The American Journal of Medicine
Volume 122, Issue 1 , Pages 42-52.e2 , January 2009

The Cost-effectiveness of Hormone Therapy in Younger and Older Postmenopausal Women

  • Shelley R. Salpeter, MD

      Affiliations

    • Department of Medicine, Santa Clara Valley Medical Center, San Jose, Calif
    • Department of Medicine, Stanford University School of Medicine, Stanford, Calif
    • Corresponding Author InformationRequests for reprints should be addressed to Shelley R. Salpeter, MD, Department of Medicine, Santa Clara Valley Medical Center, 751 S. Bascom Ave., San Jose, CA 95128
    • ,
  • Nicholas S. Buckley

      Affiliations

    • Undergraduate Program, California Institute of Technology, Pasadena
    • ,
  • Hau Liu, MD, MBA

      Affiliations

    • Department of Medicine, Santa Clara Valley Medical Center, San Jose, Calif
    • Department of Medicine, Stanford University School of Medicine, Stanford, Calif
    • ,
  • Edwin E. Salpeter, PhD

      Affiliations

    • Astronomy Department, Cornell University, Ithaca, NY

References 

  1. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75(6):1102–1109
  2. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133(12):933–941
  3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333
  4. Grady D. Postmenopausal hormones—therapy for symptoms only. N Engl J Med. 2003;348(19):1835–1837
  5. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002;137(10):834–839
  6. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004;292(16):1983–1988
  7. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19(7):791–804
  8. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women (A meta-analysis). J Gen Intern Med. 2006;21(4):363–366
  9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–338
  10. Inadomi JM. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol. 2004;16(6):535–542
  11. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ. 2005;330(7487):342
  12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712
  13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus prostestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–534
  14. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872–881
  15. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81(9):1110–1115
  16. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300–306
  17. Palmer AJ, Valentine WJ, Roze S, et al. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. Curr Med Res Opin. 2005;21(1):19–26
  18. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke. 2006;37(5):1179–1183
  19. Ghatnekar O, Persson U, Glader EL, Terent A. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care. 2004;20(3):375–380
  20. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol. 2006;163(7):589–599
  21. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study (a prospective, observational study). Ann Intern Med. 2001;135(1):1–8
  22. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47–63
  23. Sidney S, Petitti DB, Quesenberry CP. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 1997;127(7):501–508
  24. Au GK. Evaluation of the benefits and risks of hormone replacement therapy. Hong Kong Med J. 2000;6(4):381–389
  25. Farquhar CM, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2005;(3):CD004143
  26. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (Heart and Estrogen/progestin Replacement Study (HERS) Research Group). JAMA. 1998;280(7):605–613
  27. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591–2602
  28. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477
  29. Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res. 2003;114:1–5
  30. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524–3530
  31. Taplin SH, Barlow W, Urban N. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417–426
  32. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37:1249–1259
  33. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13(6):475–486
  34. Balinger AB, Anggiansah C. Colorectal cancer. BMJ. 2007;335:715–718
  35. Chan JA, Meyerhardt JA, Chan TA, et al. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24(36):5680–5685
  36. Vestergaard P, Rejnmark L, Mosekilde L. Hip fracture prevention: cost-effective strategies. Pharmacoeconomics. 2001;19(5 Pt 1):449–468
  37. Col NF, Weber G, Stiggelbout A, et al. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med. 2004;164(15):1634–1640
  38. Kim C, Kwok YS. Decision analysis of hormone replacement therapy after the Women's Health Initiative. Am J Obstet Gynecol. 2003;189(5):1228–1233
  39. Armstrong K, Chen TM, Albert D, et al. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol. 2001;98(6):996–1003
  40. Wu F, Ames R, Clearwater J, et al. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf). 2002;56(6):703–711
  41. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc. 2003;51(3):364–370
  42. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int. 2005;16(2):134–141
  43. Sanders KM, Seeman E, Ugoni AM, et al. Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int. 1999;10(3):240–247
  44. Maravic M, Le Bihan C, Landais P, Fardellone P. Incidence and cost of osteoporotic fractures in France during 2001 (A methodological approach by the national hospital database). Osteoporos Int. 2005;16(12):1475–1480
  45. Oglesby AK, Minshall ME, Shen W, et al. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol. 2003;30(7):1579–1583
  46. Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: from the cardiovascular health study. J Am Geriatr Soc. 2006;54(12):1885–1891
  47. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int. 1999;10(1):73–78
  48. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006;21(6):817–828
  49. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13(4):323–330
  50. Vestergaard P, Rejnmark L, Mosekilde L. Fracture reducing potential of hormone replacement therapy on a population level. Maturitas. 2006;54(3):285–293
  51. Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women—results of the Danish Osteoporosis Prevention Study. Maturitas. 2000;36(3):181–193
  52. Adachi JD, Loannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 2001;12(11):903–908
  53. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int. 2002;13(10):768–776
  54. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168–183
  55. Sasser AC, Rousculp MD, Birnbaum HG, et al. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues. 2005;15(3):97–108
  56. Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics. 2003;21(6):383–396
  57. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427
  58. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer). Lancet. 1997;350(9084):1047–1059
  59. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4):485–491
  60. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer. 2004;100(11):2328–2337
  61. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–3263
  62. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–741
  63. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(7):593–600
  64. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360(9337):942–944
  65. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328–332
  66. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168(5):1473–1480
  67. Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2008;168(4):425–430
  68. Laporte S, Mismetti P, Decousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermadad TromboEmbolica venosa Registry. Circulation. 2008;117:1711–1716
  69. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358:1037–1052
  70. Arias E. United States life tables, 2003. Natl Vital Stat Rep. 2006;(54):1–40
  71. Calle EE, Miracle-McMahill HL, Thun MJ, Health CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517–523
  72. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep. 2007;55(19):1–119
  73. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–741
  74. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol. 1997;104(10):1191–1195
  75. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002;287(5):591–597
  76. Smith AJ, Hall DR, Grove D. Postmenopausal hormone therapy and quality of life. Int J Gynaecol Obstet. 2006;95(3):267–271
  77. Dinger J, Zimmermann T, Heinemann LA, Stoehr D. Quality of life and hormone use: new validation results of MRS scale. Health Qual Life Outcomes. 2006;4:32
  78. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22(3):189–212
  79. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Menopause Soc. 2005;11(4):145–151
  80. Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings. J Br Menopause Soc. 2006;12(3):115–125
  81. Evio S, Pekkarinen T, Sintonen H, et al. The effect of hormone therapy on the health-related quality of life in elderly women. Maturitas. 2007;56(2):122–128
  82. 2006 Redbook: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale, NJ: Thomson PDR; 2006;
  83. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58–66
  84. U.S. Department of Labor. Bureau of Labor Statistics Data. U.S. consumer price index for medical care services for all urban consumers. http://data.bls.gov/PDQ/servlet/SurveyOutputServletAccessed August 11, 2007
  85. Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ. 2006;15(4):373–381
  86. Daly E, Vessey MP, Barlow D, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas. 1996;23(2):247–259
  87. Zubialde JP, Lawler F, Clemenson N. Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis. J Fam Pract. 1993;36(3):271–280
  88. Zethraeus N, Johannesson M, Jonsson B. A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care. 1999;15(2):352–365
  89. Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm. 2003;9(2):150–158
  90. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ. 2004;328(7436):371
  91. Botteman MF, Shah NP, Lian J, et al. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. Menopause. 2004;11(3):343–355
  92. Zethraeus N, Borgstrom F, Jonsson B, Kanis J. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care. 2005;21(4):433–441
  93. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004;164(12):1285–1292
  94. Bergkvist L, Adami HO, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130(2):221–228
  95. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91(3):264–270
  96. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control. 1996;7(4):449–457
  97. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127(11):973–980
  98. Ylikangas S, Backstrom T, Heikkinen J. Cost-effectiveness of continuous combined hormone replacement therapy in long-term use: economic evaluation based on a 9-year study in Finland. Curr Med Res Opin. 2007;23(1):57–64
  99. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538–554

 Funding: Funding source was salary support for S. Salpeter and H. Liu from Santa Clara Valley Medical Center and a Cornell Podell Emeriti Award for E. Salpeter. The institutions had no role in the design, conduct, or reporting of the study. No sponsorship from the pharmaceutical industry was provided to conduct this analysis.

 Conflict of Interest: Dr. Salpeter consulted with law firms representing Wyeth Pharmaceuticals and was paid on an hourly basis.

PII: S0002-9343(08)00953-4

doi: 10.1016/j.amjmed.2008.07.026

The American Journal of Medicine
Volume 122, Issue 1 , Pages 42-52.e2 , January 2009

Article Tools

* Image Usage & Resolution